Chewy Inc vs Cassava Sciences Inc — how do they compare? Chewy Inc trades at $22.32 (market cap $9.20B), while Cassava Sciences Inc trades at $0.93 (market cap $47.75M). The key difference: Chewy Inc is far larger — about 192.7× Cassava Sciences Inc's market cap, and Chewy Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| CHWY | FLNA | |
|---|---|---|
Market Cap | $9.20B | $47.75M |
Sector | Consumer Cyclical | Health |
52-Week High | $42.33 | $4.64 |
52-Week Low | $17.51 | $0.87 |
Enterprise Value | $9.16B | -$34.93M |
Signals from Pluang's Aura AI — not financial advice
CHWY trades at $22.38, down 0.93% on the day, with a bearish technical signal and neutral oscillators. Revenue grew to $11.86B in 2025, with net income surging to $392.74M, though margins remain thin. Recent news highlights insider selling and mixed institutional moves, while analyst consensus is strongly bullish with an $33.82 price target.
The stock offers growth potential from recurring revenue and market expansion but faces risks from competition and volatile earnings. With high valuation multiples and bearish technicals, near-term pressure may persist, but long-term prospects hinge on sustained profitability and execution against rivals like Amazon.
FLNA is trading at $0.9401, down 5.74% on the day, with a bearish technical signal from moving averages. The company shows consistent quarterly earnings beats but remains unprofitable with negative ROE of -55.79% and negative cash flow. Analyst sentiment is positive with 67% buy ratings, though the stock faces fundamental challenges with ongoing operational losses.
The outlook remains challenged by persistent losses and negative cash flow, though recent earnings beats and strong analyst support provide potential upside. Key risks include the company's ability to achieve profitability and sustain operations given current burn rate. The biotechnology focus on TSC-related epilepsy represents both opportunity and execution risk.
Trailing returns across standard periods
Latest headlines on both assets
Chewy is the largest e-commerce pet care retailer in the U.S., generating $8.9 billion in 2021 sales across pet food, treats, hard goods, and pharmacy categories. The firm was founded in 2011, acquired by PetSmart in 2017, and tapped public markets as a standalone company in 2019, after spending a couple of years developing under the aegis of the pet superstore chain. The firm generates sales from pet food, treats, over-the-counter medications, medical prescription fulfillment, and hard goods, like crates, leashes, and bowls.
Read more on CHWY →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →